Oncotarget

Research Papers:

A novel messenger RNA signature as a prognostic biomarker for predicting relapse in pancreatic ductal adenocarcinoma

Guodong Shi, Jingjing Zhang, Zipeng Lu, Dongfang Liu, Yang Wu, Pengfei Wu, Jie Yin, Hao Yuan, Qicong Zhu, Lei Chen, Yue Fu, Yunpeng Peng, Yan Wang, Kuirong Jiang _ and Yi Miao

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:110849-110860. https://doi.org/10.18632/oncotarget.22861

Metrics: PDF 655 views  |   HTML 1215 views  |   ?  


Abstract

Guodong Shi1,2,*, Jingjing Zhang1,2,*, Zipeng Lu1,2,*, Dongfang Liu1,2,*, Yang Wu1,2, Pengfei Wu1,2, Jie Yin1,2, Hao Yuan1,2, Qicong Zhu1,2, Lei Chen1,2, Yue Fu1,2, Yunpeng Peng1,2, Yan Wang3, Kuirong Jiang1,2 and Yi Miao1,2

1Pancreas Center, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

2Pancreas Institute of Nanjing Medical University, Nanjing 210029, China

3Endoscopy Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

*These authors contributed equally to this work

Correspondence to:

Kuirong Jiang, email: jiangkuirongnjmu@sina.com

Yi Miao, email: miaoyi@njmu.edu.cn

Keywords: predictive signature; biomarker; bioinformatics; pancreatic ductal adenocarcinoma; relapse-free survival

Received: June 16, 2017     Accepted: November 04, 2017     Published: December 02, 2017

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) death rate and recurrence rate have remained obstinately high. Current methods can not satisfy the need of predicting cancer relapse accurately. Utilizing expression profiles of 10 GEO datasets (N = 774), we identified 154 differentially expressed genes (DEGs) between PDAC and normal pancreas tissue or paracancerous tissue. Next we built a 16-mRNA-based signature by means of the LASSO COX regression model. We also validated the prognostic value of the signature. Patients were classified into high-risk and low-risk group according to the signature risk score; 1 year RFS was 45% (95% CI: 31.6%–63.9%) for high-risk group in contrast to 92.5% (95% CI: 86.3%–99.1%) for low-risk group. Moreover, it could predict RFS well in cases with the receipt of different treatment modalities. The 16-mRNA-based signature was an independent and powerful prognostic biomarker for RFS for PDAC patients (HR = 7.74, 95% CI: 3.25–18.45, p < 0.0001).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22861